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Received September 22, 2014; accepted August 23, 2015AbstractBackground: Gami-hyunggyeyeongyotang (GMHGYGT) is a polyherbal medicine derived from an oriental prescription traditionally used in the
treatment of allergic diseases such as allergic rhinitis (AR). This study aimed to evaluate the effects of GMHGYGT on ovalbumin (OVA)
sensitization/challenge-induced AR in BALB/C mice, through examination of allergic inflammatory response regulation, as well as examination
of human mast cells (HMC-1).
Methods: Nasal symptoms were evaluated in the OVA-induced allergic rhinitis mouse model, and total immunoglobulin (Ig)E and OVA-specific
IgE levels in serum were investigated. Eosinophil infiltration and thickness of the nasal mucosa, and levels of interleukin (IL)-1b and caspase-1
were also measured by immunohistochemistry. Additionally, the effect of GMHGYGT on the phorbol-12-myristate-13-acetate plus calcium
ionophore A23187-induced phosphorylation of extracellular signal-regulated kinase, C-Jun N-terminal kinase and p38 in HMC-1 cells was
investigated.
Results: GMHGYGTwas demonstrated to have antiallergic effects on the nasal symptoms of the OVA-induced mouse model, decreasing serum
levels of OVA-specific IgE and levels of the cytokines IL-5, IL-6, IL-1b, monocyte chemotactic protein-1, and macrophage inflammatory
protein-2. GMHGYGT reduced the number of eosinophils in the nasal mucosa and thickness of the nasal septum, and inhibited the expression of
IL-1b and caspase-1. Moreover, it inhibited the phosphorylation of extracellular signal-regulated kinase and C-Jun N-terminal kinase, as well as
the activation of nuclear factor-kB on protein level in HMC-1 cells.
Conclusion: These results suggest that GMHGYGT has therapeutic potential for the treatment of allergic rhinitis.
Copyright © 2015, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Allergic rhinitis (AR) is an inflammatory disease of the
nasal mucosa.1,2 It induces an immunoglobulin (Ig)E-mediated
reaction resulting from inflammation of the airway mucosa
with hypersensitivity caused by seasonal or perennialConflict of interest: The authors declare that they have no conflicts of interest
related to the subject matter or materials discussed in this article.
* Corresponding author. Dr. Hyuk-Sang Jung, College of Korean Medicine,
Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul, 130-701,
South Korea.
E-mail address: jhs@khu.ac.kr (H.-S. Jung).
http://dx.doi.org/10.1016/j.jcma.2015.08.012
1726-4901/Copyright © 2015, the Chinese Medical Association. Published by El
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).responses to specific allergens.3,4 Approximately 500 million
people are affected by AR around the world, and it presents
with symptoms of sneezing, itching, and respiratory obstruc-
tion causing pain.1,5 Besides these symptoms, AR can also
lead to other inflammatory diseases such as asthma, rhinosi-
nusitis, allergic conjunctivitis, otitis media with effusion, nasal
polyp, tubal dysfunction, and adenoid hypertrophy.6
AR is caused by allergic mediators such as mast cells, in-
flammatory cytokines, eosinophils, and histamine.7 They have
been recognized to play a key role in the inflammatory reaction,
as the mediators interact with each other to cause acute in-
flammatory reactions against an allergen upon exposure.8 At thesevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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noglobulin (Ig)E receptors on the basophil surface, which can
trigger the release of inflammatory cytokines and histamine.9
These steps contribute to increasing the recruitment of inflam-
matory cells and eosinophil migration to affected tissue.10
Even though there are multiple treatments available for AR
such as medical treatment, immunotherapy, or surgery, the
rates of side effects and recurrence are high after stopping
medication.11 Therefore, alternative treatments with improved
drug stability are needed.12 Herbal medicines have been used
for the traditional treatment of various allergic diseases to
maintain immune balance. Hence, many studies aiming to find
an appropriate treatment for AR have focused on traditional
medicines, which have fewer side effects and are more stable
than the currently used drugs.13
Gami-hyunggyeyeongyotang (GMHGYGT) is a polyherbal
medicine derived from the Chinese traditional prescription
hyunggyeyeongyotang (HGYGT) for the treatment of runny
nose, sneezing, and congestion.14 Some experimental studies
have reported that HGYGT and GMHGYGT had effects on
fever, pain, and edema.15 Previous reports also indicated that
HGYGT has anti-allergy and anti-inflammatory effects, as
well as experimental effects on histamines and serotonin.16
However, the anti-allergy effect and mechanism of
GMHGYGT remain unknown. The present study aimed to
evaluate the effect of GMHGYGT on ovalbumin (OVA)
sensitization/challenge-induced AR in BALB/C mice through
regulation of the allergic inflammatory response. Nasal
symptoms were evaluated in an OVA-induced allergic rhinitis
mouse model. Cytokine, total IgE, and OVA-specific IgE
levels in the serum were investigated to verify the effects of
GMHYGYT. Eosinophil infiltration and thickness of the nasal
mucosa, and levels of interleukin (IL)-1b and caspase-1 were
also measured via immunohistochemistry. To provide more
evidence for verification of the anti-AR mechanism, mitogen-
activated protein kinases (MAPKs), nuclear factor (NF)-kB,
and inhibitor of NF-kB (IkB-a) were examined through
western blotting in HMC-1 cells in vitro.Table 1
Contents of Gami-hyunggaeyeongyotang (GMHGYGT).
Herbal medicine Scientific name
Schizonepetae Spica Schizonepeta tenuifolia Briquet
Forsythia Fructus Forsythia viridissima Lindley
Saposhnikovia Radix Saposhnikovia divaricata Schiskin
Angelicae Radix Angelica a cutiloba kitagawa
Cnidii Rhizoma Cnidium officinale Makino
Paeoniae Radix alba paeonia lactiflora pallas
Angelicae dahuricae Radix Angelica dahurica Bentham et Hooker
Bupleuri Radix Bupleurum falcatum Linne
Scutellariae Radix Scutellaria baicalensis Georgi
Aurantii Fructus Immaturus Citurus aurantium Linne
Gardeniae Frutus Gardenia jasminoides Ellis
Platycodi Radix Platycodon grandiflorum A. De cando
Glycyrrhizae Radix Glycyrrhiza uralensis Fischer
Ulmi Cortex Ulmus macrocarpa Hance
Xanthii Fructus Xanthium strumarium Linne
Magnoliae Flos Magnolia kobus De Candolle
Rubiae Radix Rubia akane Nakai2. Methods2.1. ReagentsPhorbol 12-myristate 13-acetate (PMA) and calcium iono-
phore A23187 were purchased from SigmaeAldrich (St.
Louis, MO, USA). Aqueous nonradioactive cell proliferation
assay from Promega Corporation (Madison, WI, USA),
Iscove's Modified Dulbecco's Medium and fetal bovine serum
from Gibco BRL (Grand Island, NY, USA), and streptomycin
from Invitrogen (Carlsbad, CA, USA). Antibodies to phos-
phorylated extracellular signal-regulated kinase (ERK), ERK,
phosphorylated p38, p38, phosphorylated C-Jun N-terminal
kinase (JNK) and JNK were purchased from Cell Signaling
Technology (Danvers, MA, USA), to NF-kB, IkB-a, Lamin B,
and actin from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), peroxidase IgG from Jackson ImmunoResearch (West
Grove, PA, USA), and to caspase-1 and IL-1b from Santa Cruz
Biotechnology. Chemical reagents diaminobenzidine tetra-
chloride, NiCl2$H2O, Triton™ X-100, and methyl Green were
obtained from SigmaeAldrich.2.2. Preparation of GMHGYGTHerbal components of GMHGYGT were purchased from
Omni Herb Inc. (Andong-si, Gyeongbuk, Korea). The sub-
stances and composition of GMHGYGT are presented in Table
1. All herbs were authenticated by Professor Youngmin Bu, a
medical botanist in the Department of Herbology, College of
Korean Medicine, Kyung Hee University, Seoul, Korea;
additionally, voucher specimens were preserved at Kyung Hee
University. Herbs used in GMHGYGT were mixed according
to the ratios listed in Table 1. Dried GMHGYGTwas extracted
as follows. Mixed GMHGYGT (208 g) was boiled in 2.1 L
distilled water (95e100C) for 2 hours, and filtered using
Whatman filter paper No. 3 (Maidstone, Kent, UK). The
filtered extract was concentrated in a rotary vacuum evapo-
rator then lyophilized to yield 34 g of dried powder (yield ratioVoucher specimen number Amount Used (g)
A051 3
KHY01 3
KHY02 3
KA015 3
A061 3
A028 3
KHY03 3
A011 3
A027 3
KHY05 2
KHY06 3
le KHY09 3
KHY010 3
KHY04 6
A057 4
KHY07 2
KHY08 2
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20C until use. The chromatogram patterns of high-perfor-
mance liquid chromatography (HPLC) was shown in Fig. S1.2.3. AnimalsSix-week-old female BALB/c mice were purchased from
Nara Biotech (Gangnam-gu, Seoul, Korea). All animal ex-
periments were approved according to guidelines of the Kyung
Hee University Institutional Animal Care and Use Committee
(KHUASP(SE)-13-006). The mice were housed under
controlled temperature (23 ± 3C) with a relative humidity of
40e60% and 12 hour light/dark cycles. Food and water were
provided ad libitum.2.4. Elicitation and group classification of AR modelThe 6-week-old female BALB/C mice were divided into
four groups (n ¼ 8 per group): (1) control group; (2) OVA
sensitized (OVA) group; (3) GMHGYGT group; and (4)
cetirizine-treated (Cet) group. After the mice were stabilized
for 1 week, they were OVA-sensitized by intraperitoneal in-
jection of 50 mg OVA (chicken egg albumin; Sigma) in 200 mL
of phosphate-buffered saline (PBS) containing 2 mg aluminum
hydroxide (Alum; Sigma) on Day 0, Day 7, and Day 14. One
week after the last injection on Day 21, the mice were chal-
lenged with 20 mL PBS containing 50 mg/mL OVA into the
bilateral nasal cavities. From Day 21 to Day 31, mice in the
Control and OVA groups were given saline by peroral
administration, and those in the Cet group received 10 mg/kg
cetirizine hydrochloride (Allertec Tab; Korean Drug, Seoul,
Korea), and the GMHGYGT group was orally administered
134 mg/kg GMHGYGT 1 hour before intranasal challenge of
OVA under the same conditions. Cetirizine, a second-
generation antihistamine, is a major metabolite of hydroxy-
zine and a racemic selective H1 receptor inverse agonist used
in the treatment of allergies, angioedema, and urticaria.17 In
this study, cetirizine was used as a positive control.2.5. Nasal symptom evaluationThe mice (6 weeks old, female) were administrated OVA
intranasally, and the nasal symptoms were evaluated 2 minutes
later by counting the time of nasal rubbing and number of
sneezing events for 10 minutes. This procedure was carried out
for 10 days starting from Day 21 (Fig. S2). Three hours after
the last observation, the mice were anesthetized with sodium
pentobarbital. The blood was then collected via cardiac
puncture, and the nasal mucosa and tissue were taken and
stored at 20C until use.2.6. Measurement of total IgE and OVA-specific IgE in
serumBlood of the mice from each experimental group was
collected via cardiac puncture. The blood was centrifuged to
obtain serum, from which the total IgE and OVA-specific IgEwere quantified using an enzyme-linked immunosorbent assay
(ELISA).2.7. Measurement of cytokines in the serumTo demonstrate the effect of GMHGYGT on allergic re-
sponses in the AR model, the levels of IL-5, IL-6, IL-1b,
monocyte chemoattractant protein (MCP)-1, and macrophage
inflammatory protein (MIP)-2 were measured using a mouse
cytokine/chemokine magnetic bead panel kit (EMD Millipore,
Billerica, MA, USA). The plate was washed with 200 mL wash
buffer for 10 minutes at room temperature, and then 25 mL
standard solution and assay buffer were added to the appro-
priate wells. The standard serum matrix solution (25 mL) was
added to the background well. Diluted serum was mixed with
assay buffer, and 25 mL of beads was added to all wells. The
plate was then covered by foil, and placed at room temperature
for 20 minutes. Next, 25 mL of detection antibody was added
to the wells and reacted for 1 hour at room temperature, after
which streptavidinephycoerythrin were added to each well
and mixed for 30 minutes. After washing twice, 150 mL sheath
fluid was added to the wells and mixed for 5 minutes. The
plate was measured with the Luminex 200 System (Luminex,
Austin, TX, USA).2.8. Histological evaluationThe heads of the mice were fixed using 10% formalin, then
the nasal tissue was separated from the muscle and skin of the
head. Nasal tissue was decalcified in 10% EDTA buffer for
14 days. The tissue was embedded in paraffin and sectioned to
5 mm, and the slides were stained with hematoxylin and eosin.
The infiltration of eosinophils and thickness of the nasal mu-
cosa were observed.2.9. Immunohistochemical stainingAR tissue was tested by immunohistochemical staining.
AR tissue sections were washed three times with PBS for
5 minutes, then reacted with 0.3% H2O2 for 10 minutes.
Tissue was reacted for 1 hour in blocking solution, which was
a mixture of PBS with 10% normal serum (Jackson Immuno
Research). The tissue was then washed three times, and
treated with primary antibody overnight at 4C. Caspase-1
and IL-1b (Santa Cruz Biotechnology) were used as the
primary antibodies in a solution with a mixture of bovine
serum albumin (GenDepot, Katy, TX, USA) and Triton X-
100 with PBS. After reaction, the tissue was incubated with
peroxidase IgG for 1 hour. It was then reacted with dia-
minobenzidine tetrachloride (Sigma) mixed with NiCl2$H2O
(Sigma). Finally, the tissue was stained with Methyl Green as
a counter stain.2.10. HMC-1 cell cultureHMC-1 cells were provided by Prof. H.M. Kim (Depart-
ment of Pharmacology, Kyung Hee University). The HMC-
188 Y.-S. Im et al. / Journal of the Chinese Medical Association 79 (2016) 185e1941 cell line is useful for studying cytokine activation pathways
in immediate allergic reactions.18,19 HMC-1 cells were incu-
bated in Iscove's Modified Dulbecco's Medium with 100 U/mL
penicillin, 100 mg/mL streptomycin, and 10% heat-inactivated
fetal bovine serum at 37C, 5% CO2, and 95% humidity.2.11. MTS assay for cell viabilityCell viability was tested by the MTS colorimetric assay.
MTS assay is using conversion of the tetrazolium salt into a
colored aqueous soluble formazan, produced by mitochondrial
activity of viable cells. HMC-1 cells (1  105) were plated in
96-well plates with various GMHGYGT concentrations
(0.1 mg/mL, 1 mg/mL, 10 mg/mL, 50 mg/mL, and 100 mg/mL),
and the cells were incubated for 24 hours in a 37C incubator.
MTS solution (2 mg/mL) was added to each well, and the cells
were placed in an incubator for an additional 2 hours at 37C.
The optical density of the 96-well culture plates was measured
at 490 nm with an ELISA reader. The formazan optical density
of the untreated control cells was deemed to represent 100%
viability.2.12. Western blot analysisHMC-1 cells (5  106) were treated with various
GMHGYGT concentrations (1 mg/mL, 10 mg/mL, and 100 mg/
mL) for 1 hour, stimulated with PMA and A23187, and
incubated for an additional 2 hours for nuclear proteins, and 30
minutes for MAPKs. Western blot analysis was performed on
the cell extracts. Harvested cells were treated by a detergent
lysis procedure using lysis buffer to obtain the cell extract [4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
KCl, MgCl2, dithiothreitol, phenylmethanesulfonyl fluoride,
NaCl glycerol, EDTA]. Samples were heated at 95C for
5 minutes and centrifuged. Proteins were then resolved by
10% sodium dodecyl sulfate-polyacrylamide gel electropho-
resis, then electrotransferred to nitrocellulose membranes. The
membrane were blocked for 1 hour with 1 L phosphate-buff-
ered saline (PBS) with 0.1% Tween 20 (PBST) containing 5%
skimmed milk, and then incubated with primary antibodies
overnight at 4C. Blots were incubated with peroxidase-
conjugated secondary antibodies at room temperature, and
the antibody-specific proteins were visualized by an enhanced
chemiluminescence procedure, using an enhanced chem-
iluminescence detection reagent (Amersham Pharmacia
Biotech, Piscataway, NJ, USA).2.13. Statistical analysisThe data of symptom scores, eosinophil infiltration in nasal
mucosa, expression of caspase-1 and IL-1b were analyzed by
use of nonparametric KruskaleWallis analysis of variance and
ManneWhitney U test. The data of IgE level, proin-
flammatory cytokines and in vitro assay were analyzed for
statistical significance by one-way analysis of variance, fol-
lowed by Dunnett's multiple comparison test. Statistical
analysis was presented using the GraphPad PRISM Software(Graphpad Software Inc., La Jolla, CA, USA). Data were
presented as mean ± standard error of the mean, and p < 0.05
was considered to be significant.
3. Results3.1. Effects of GMHGYGT on behavior in rhinitis mouse
modelFrom Day 21, the frequency of rubbing was measured in
the OVA-induced rhinitis model. The result indicated that
there were 150 ± 5.79 events in the OVA group; a significant
increase from the 100.4 ± 7.22 events observed in the Control
group. The rubbing value of the Cet group was 55.8 ± 6.13,
while that of the GMHGYGT group was 76.6 ± 6.31. The
GMHGYGT group demonstrated a significant decrease
compare with the OVA group (Fig. 1A and B).
The number of sneezing events was counted for 10 days. In
the Control group, 31.4 ± 4.08 events occurred, while
88.2± 9.05 were observed in the OVA group. Again, the number
in the OVA group was significantly higher than in the Control
group. The number of sneezes was only 16.4 ± 0.94 in the Cet
group and 25.8 ± 3.61 in the GMHGYGT group; also repre-
senting significant decreases compared to the OVA group
(Fig. 1C and D).
As a preliminary study to determine the most effective dose
of GMHGYGT on the OVA-induced AR murine model, we
tested the inhibitory effect of GMHGYGT in two doses
(13.4 mg/kg and 134 mg/kg). The number of sneezing or nasal
rubbing events was reduced by GMHGYGT treatment in a
dose-dependent manner (Fig. S3).3.2. Effect of GMHGYGT on IgE and OVA-specific IgE
levels in serum of the AR modelThe total serum IgE level of the OVA group (2652.3 ± 154.6
ng/ml) was higher than in the Control group (1076.5± 144.4 ng/
ml). The group administered cetirizine showed a significant
decreased compared to the OVA group. IgE production was
inhibited in the GMHGYGT group (2341.7 ± 160.7 ng/ml;
Fig. 2A). The serum OVA-specific IgE level was 12.10 ± 1.46
Unit/ml in the OVA group, which was significantly higher than
in the Control group (4.84 ± 0.83 Unit/ml). The serum IgE level
in the Cet group (7.11 ± 0.14 Unit/ml) and GMHGYGT group
(7.38 ± 1.16 Unit/ml) both decreased significantly compared
with the OVA group (Fig. 2B).3.3. Effect of GMHGYGT on cytokine and chemokine in
serum of AR modelThe serum concentrations of IL-5, IL-6, IL-1b, MCP-1, and
MIP-2 in the OVA group were also significantly higher than
the Control group (Table 2). IL-5, IL-6, IL-1b, MCP-1, and
MIP-2 levels of the GMHGYGT group were significantly
reduced compared with the OVA group. For the Cet group,
only the levels of MCP-1 and MIP-2 were significantly lower
than in the OVA group.
Fig. 2. Effect of Gami-hyunggyeyeongyotang on IgE and OVA-specific IgE levels in serum of the allergic rhinitis model. (A) Total serum IgE levels. (B) OVA-
specific IgE levels in serum. Total IgE and OVA-specific IgE were measured by enzyme-linked immunosorbent assay. Columns and error bars represent the
mean ± standard error. *p < 0.01, significantly different from the Control group. **p < 0.05, significantly different from the OVA group. IgE ¼ immunoglobin E;
OVA ¼ ovalbumin.
Table 2
Effects of GMHGYGT on cytokine serum levels of allergic rhinitis model.
Control OVA OVAþCet OVAþGMHGYGT
IL-5 (pg/mL) 12.81 ± 1.81 26.55 ± 2.64a 42.30 ± 4.78 11.71 ± 71c
IL-6 (pg/mL) 7.52 ± 1.45 26.75 ± 2.52a 32.75 ± 5.54 16.14 ± 2.85b
IL-1b (pg/mL) 4.26 ± 0.43 6.24 ± 0.60a 5.11 ± 0.60 4.47 ± 0.45b
MCP-1 (pg/mL) 19.71 ± 2.74 33.50 ± 3.03a 21.33 ± 3.19c 15.22 ± 2.02c
MIP-2 (pg/mL) 44.87 ± 7.59 78.45 ± 5.23a 57.21 ± 6.73b 60.24 ± 6.32b
Data represent mean ± standard error.
ap < 0.01, significantly different from the Control group. bp < 0.05 and cp < 0.01, significantly different from the OVA group.
Fig. 1. Time course of the development of nasal rubbing and sneezing induced by antigen in mice sensitized with OVA and aluminum hydroxide. Clinical scores
such as sneezes and nasal rubs were measured for 10 minutes after the last intranasal challenge from Day 21 to Day 30. (A) Time of nasal rubbing each day.
(B) Total time of nasal rubbing for 10 days. (C) Number of sneezes each day. (D) Total number of sneezes for 10 days. Data represent the mean ± standard error.
*p < 0.01, significantly different from the Control group. **p < 0.01, significantly different from the OVA group. OVA ¼ ovalbumin.
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infiltration of eosinophilsThe number of infiltrated eosinophils in the OVA group
was significantly higher than in the Control group. Regarding
the Cet and GMHGYGT groups, the numbers were signifi-
cantly reduced compared with the OVA group (Fig. 3A and
B). The nasal mucosa thickness of the OVA group was
17.8 ± 2.7 mm; also demonstrating a significant increase
compared with the Control group (10.8 ± 1.3 mm). The Cet
group demonstrated a thickness of 10.8 ± 1.5 mm, while the
GMHGYGT group had a thickness of 9.8 ± 1.8 mm. Both
groups showed significantly decreased nasal mucosa thickness
(Fig. 3A and C).Fig. 3. Histological changes of nasal mucosa and infiltration of eosinophils (arrows
septum in nasal mucosa (magnification: 40, 400, and 1000). Lane 3 marked eo
by staining with Harris hematoxylin. OVA þ Cet and OVA þGMHGYGT groups
GMHGYGT (134 mg/kg), respectively, 1 hour before intranasal challenge with OVA
bars represent the mean ± standard error. *p < 0.01, significantly different from th
OVA group. Cet ¼ cetirizine; GMHGYGT ¼ Gami-hyunggyeyeongyotang; OVA3.5. Immunohistochemistry of nasal mucosa and
expression of caspase-1 and IL-1bImmunohistochemistry was performed to measure the levels
of caspase-1 and IL-1b expression in the OVA-induced AR
mouse model. Caspase-1 expression in the nasal septum of the
GMHGYGT group was significantly lower than in the OVA
group (Fig. 4), while the decrease in IL-1b expression was not
significant.3.6. Effect of GMHGYGT on PMA plus A23187-
stimulated MAPK activationTo measure the MAPKs of mast cells treated with
GMHGYGT, western blotting was performed using HMC-1 cells.
Phosphorylated-ERK and phosphorylated-JNK were inhibited) in the nasal mucosa of the allergic rhinitis model. (A) Thickness of the nasal
sinophil infiltration. Eosinophil infiltration to the nasal mucosa was determined
were orally treated with cetirizine hydrochloride (10 mg/kg body weight) or
. Control and OVA groups were treated with distilled water. Columns and error
e Control group. **p < 0.05 and ***p < 0.01, significantly different from the
¼ ovalbumin.
Fig. 4. Inhibitory effects of Gami-hyunggyeyeongyotang on caspase-1 and IL-1b in the nasal mucosa of the allergic rhinitis mouse model. The areas of the nasal
septum stained violet (A: magnification: 400) indicate caspase-1 and IL-1b expression. Nasal mucosa was stained with diaminobenzidine and counter stained
with methyl green. Expression of caspase-1 and IL-1b in the nasal tissue was measured using Image J software. Columns and error bars represent the
mean ± standard error. *p < 0.01, significantly different from the Control group. **p < 0.05 and ***p < 0.01, significantly different from the OVA group.
IL ¼ interleukin.
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contrast, phosphorylated-p38 had no significant change.3.7. Effect of GMHGYGT on PMA plus A23187-
stimulated NF-kB activation and IkB-a degradationTo measure the NF-kB activation and IkB-a degradation in
mast cells treated with GMHGYGT, western blotting was
performed with HMC-1 cells. GMHGYGT inhibited the
degradation of IkB-a in a concentration-dependent manner.
GMHGYGT significantly decreased IkB-a degradation
compared with the OVA group at a concentration of 100 mg/
mL. Moreover, GMHGYGT also demonstrated concentration-
dependent inhibition of NF-kB, with significant reduction at a
concentration of 100 mg/mL compared to the OVA group
(Fig. 6).
4. Discussion
In the present study, the effect of GMHGYGT treatment
on an OVA-induced AR mouse model was examined.
GMHGYGT effectively ameliorated the allergic symptoms
and suppressed the production of total and OVA-specific
serum IgE. It also inhibited the expression of IL-5, IL-6, IL-
1b, MCP-1, and MIP-2 in serum of AR mice. In addition,suppression of the NF-kB signaling pathway was observed in
HMC-1 cells treated with GMHGYGT.
The allergic inflammatory response is initiated within mi-
nutes of allergen exposure and is primarily due to the release
of mediators by mast cells, including cytokines (IL-4, IL-5,
and IL-6), chemotactic factors, and enzymes.9 The net effect
of these mediators is to produce the early symptoms of AR,
and to stimulate the production and adhesion of circulating
leukocytes, especially eosinophils, as well as their infiltration
into the local tissue.20 OVA sensitization and challenge in
animal models leads to an increase in the OVA-specific IgE in
plasma and infiltration of inflammatory cells in epithelium and
subepithelium of the nasal mucosa.21 In the present study,
GMHGYGT remarkably inhibited the symptoms of rhinitis
including the nasal rubbing time, number of sneezing events,
and the increase in thickness of the nasal septum. In addition,
the number of infiltrated eosinophils and the nasal mucosa
thickness were significantly lower in the GMHGYGT group
compared with the OVA group. These results demonstrated
that GMHGYGT alleviated the allergic immune response in
the AR model by reducing the infiltration of eosinophils.
Exposure to allergen initiates a cascade of biochemical and
cellular events, resulting in the synthesis and release of IgE.
This IgE-mediated response is marked by the T helper 2
immunological response, with mast cell and eosinophil
Fig. 5. Effect of GMHGYGTon PMA plus A23187-stimulated MAPK activation. HMC-1 cells were pretreated with GMHGYGT for 1 hour and then stimulated by
30 minutes incubation with PMA and A23187. The relative levels of expression of the MAPKs were measured using Image J. Columns and error bars represent the
mean ± standard error. *p < 0.01, significantly different from normal. **p < 0.05 and ***p < 0.01, significantly different from PMA and A23187 alone.
GMHGYGT ¼ Gami-hyunggyeyeongyotang; MAPK ¼ mitogen-activated protein kinase; PMA ¼ phorbol 12-myristate 13-acetate.
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IgE, with significant reduction of the OVA-specific IgE. This
indicated that GMHGYGT inhibited the allergic response,
especially through the reduction of OVA-specific IgE.
T helper 2 cells produce cytokines such as IL-5, IL-6, MCP,
andMIP, which induce hypersensitivity of eosinophils and mast
cells, and the production and differentiation of B lympho-
cytes.22 IL-5 regulates the growth and differentiation of eo-
sinophils, and serves as an essential signal for their movement
into inflammatory tissue upon antigen exposure.23 IL-6 has the
important role of inducing cell generation, growth, survival,
and migration during inflammatory reaction.24 MCP and MIP
are the key factors that affect the movement or activation of
eosinophils and neutrophils.25,26 In this study, the GMHGYGT
group appeared to have significant reduction in the serum levels
of IL-5, IL-6, MCP-1, and MIP-2 compared to the OVA-
induced group. These results suggest that GMHGYGT might
influence the production of IL-5, IL-6, MCP-1, and MIP-2
during the process of antigen-specific IgE production.
The activation of caspase-1 can induce inflammation.
Caspase-1 contains an N-terminal caspase recruitment domainthat is capable of activating NF-kB associated with inflam-
matory responses.27 Caspase-1 contributes to the activation
of IL-1b by separating IL-1b from precursors.28 IL-1b plays a
role as a highly inflammatory cytokine, and is considered
the host immune defensor.29 In the present study, GMHGYGT
considerably decreased the expression of caspase-1 and IL-
1b in the nasal mucosa tissue, as observed through immuno-
histochemistry analysis. These results suggest that
GMHGYGT can attenuate allergic inflammation by sup-
pressing the expression of IL-1b and caspase-1.
Mast cells are activated by the synthesis of cytokines that
can damage the target inflammatory tissue.9 In this study, the
MAPKs cascade and NF-kB pathway were investigated via
protein levels in HMC-1 cells. MAPKs including ERK, JNK,
and p38 are responsible for various functions including the
proliferation, differentiation, and apoptosis of cells, cellular
response to cytokines and stress control.30 ERK is essential for
cell proliferation and differentiation in the signaling pathways.
JNK and p38 are induced by environmental stresses and
growth factors, and are known to promote cell growth inhi-
bition, inflammatory response, and apoptosis.31e33 In the
Fig. 6. Effect of GMHGYGT on PMA plus A23187-stimulated NF-kB and phosphorylated-NF-kB activation, along with IkB-a and p-IkB-a degradation. HMC-
1 cells were pretreated with GMHGYGT for 1 hour and stimulated by 2 hours incubation with PMA and A23187 (A, D). The relative expression levels of IkB-a,
phosphorylated-IkB-a, NF-kB and phosphorylated-NF-kB were measured using Image J (B, C, E, F). Columns and error bars represent the mean ± standard error.
*p < 0.05 and **p < 0.01, significantly different from normal. ***p < 0.05 and ****p < 0.01, significantly different from PMA and A23187 alone.
GMHGYGT ¼ Gami-hyunggyeyeongyotang; IkB ¼ inhibitor of NF-kB; NF-kB ¼ nuclear factor-kB; PMA ¼ phorbol 12-myristate 13-acetate.
193Y.-S. Im et al. / Journal of the Chinese Medical Association 79 (2016) 185e194present study, GMHGYGT inhibited expression of
phosphorylated-ERK and phosphorylated-JNK. This means
that GMHGYGT inhibited the inflammatory reaction in mast
cells involved in the production of inflammatory cytokines
through blocking the phosphorylation of ERK and JNK. In
addition, GMHGYGT inhibited the phosphorylation of NF-
kB. These results indicate that GMHGYGT could regulate the
expression of proinflammatory cytokines through the inacti-
vation of phosphorylated-IkB and translocation of NF-kB into
the nucleus.
In conclusion, our study demonstrated GMHGYGT to have
an antiallergic effect by improving the symptoms of rhinitis,
and inhibiting the release of allergic mediators in the OVA-
induced AR model. In addition, GMHGYGT has anti-
inflammatory activity by suppressing the production of in-
flammatory cytokines such as IL-5, IL-6, IL-1b, MCP-1, and
MIP-2, via the ERK, JNK, and NF-kB pathways in HMC-
1 cells. These results suggest that GMHGYGT might be a
good therapeutic drug for the treatment of allergic rhinitis.
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